Beirne Wealth Consulting Services, LLC Mannkind Corp Transaction History

Beirne Wealth Consulting Services, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 03, 2022	SELL	$4.05 - $5.37 $117,450 - $155,730	-29,000 Closed	0 $0
Q3 2021 Nov 09, 2021	SELL	$3.89 - $5.48 $38,900 - $54,800	-10,000 Reduced 25.64%	29,000 $126,000
Q2 2021 Aug 10, 2021	SELL	$3.61 - $5.45 $7,220 - $10,900	-2,000 Reduced 4.88%	39,000 $212,000
Q4 2020 Feb 03, 2021	SELL	$1.79 - $4.04 $166,828 - $376,528	-93,200 Reduced 69.45%	41,000 $128,000
Q2 2020 Jul 31, 2020	BUY	$0.94 - $2.21 $37,600 - $88,400	40,000 Added 42.46%	134,200 $235,000
Q1 2020 Apr 28, 2020	BUY	$0.84 - $1.76 $840 - $1,760	1,000 Added 1.07%	94,200 $97,000
Q3 2019 Nov 07, 2019	BUY	$1.04 - $1.44 $31,200 - $43,200	30,000 Added 47.47%	93,200 $117,000
Q2 2019 Jul 25, 2019	SELL	$1.09 - $1.88 $9,265 - $15,980	-8,500 Reduced 11.85%	63,200 $73,000
Q1 2019 May 14, 2019	BUY	$1.14 - $2.25 $68,970 - $136,125	60,500 Added 540.18%	71,700 $141,000
Q4 2018 Feb 14, 2019	BUY	$1.02 - $2.05 $11,424 - $22,959	11,200 New	11,200 $12,000

245

148M

1.62M

802K

Ticker MNKD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 257,338,000
Market Cap $1.53B
Description
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...

Get notified when there are updates to the investment portfolio of Beirne Wealth Consulting Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Beirne Wealth Consulting Services, LLC with notifications on news.